Cargando…
Eight Years of Real-Life Experience with Smoothened Inhibitors in a Swiss Tertiary Skin Referral Center
SIMPLE SUMMARY: Vismodegib and sonidegib are targeted therapies inhibiting the hedgehog pathway, a key driver in the pathogenesis of basal cell carcinoma (BCC). Hedgehog inhibitors (HhIs) are first-line therapy for locally advanced basal cell carcinoma (laBCC), metastatic basal cell carcinoma (mBCC)...
Autores principales: | Grossmann, Lara E., Ramelyte, Egle, Nägeli, Mirjam C., Dummer, Reinhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139771/ https://www.ncbi.nlm.nih.gov/pubmed/35626100 http://dx.doi.org/10.3390/cancers14102496 |
Ejemplares similares
-
Swiss Recommendations for Cutaneous Basal Cell Carcinoma
por: Ramelyte, Egle, et al.
Publicado: (2022) -
Recurrent squamous cell carcinoma of the perianal skin: a case report
por: Staeger, Ramon, et al.
Publicado: (2020) -
Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome
por: Simic, Dario, et al.
Publicado: (2021) -
The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
por: Dummer, Reinhard, et al.
Publicado: (2023) -
Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma
por: Lang, Claudia C. V., et al.
Publicado: (2020)